TWST: AI Drug Discovery Hopes Will Be Tested By Sector Headwinds

The analyst fair value estimate for Twist Bioscience has been lifted from $64.38 to $71.10. Analysts point to a higher assumed revenue growth rate, a richer future P/E and sector research that highlights the company’s growing role in next generation drug discovery and development as key factors in the new price target.

Analyst Commentary

Recent Street research on Twist Bioscience highlights a mix of optimism about the company’s role in next generation drug discovery and development and caution around sector level headwinds. This combination helps explain the higher fair value estimate and the range of price targets on the stock.

Bullish Takeaways

Bullish analysts emphasize Twist Bioscience’s growing exposure to next generation drug discovery and development as a key pillar of their higher price targets, linking that exposure to potential long term revenue expansion and earnings power.
The initiation with a relatively high price objective suggests confidence that the current valuation can be supported by the company’s potential to compound growth over multiple years, provided execution on its drug discovery related opportunities stays on track.
Research coverage across several firms, with multiple price target increases, points to stronger institutional attention on Twist Bioscience. Some analysts see this as a support for liquidity and for a more refined view on the company’s long term business model.
Bullish analysts frame Twist Bioscience as one of the preferred stocks in life science tools for investors seeking exposure to possible multi year growth compounding opportunities in drug discovery and development.

Bearish Takeaways

Even optimistically inclined analysts flag sector headwinds, including pressure on biotech and academic research spending and exposure to China, as key risks that could weigh on Twist Bioscience’s near term execution and on how quickly growth translates into earnings.
Some research explicitly states a preference to wait a few quarters before becoming more aggressive on the broader life science tools sector. This implies that timing and sector cyclicality remain important considerations for investors looking at Twist Bioscience stock.
The view that the sector has not yet returned to pre Covid performance levels underlines the possibility that, despite a higher fair value estimate, market sentiment toward Twist Bioscience could stay sensitive to macro and funding related news.
Bearish analysts, or those more cautious, may see the richer future P/E assumptions used in target setting as vulnerable if new growth drivers in drug discovery and development take longer than expected to materialize in reported financials.

What’s in the News for Twist Bioscience

ARK Invest trimmed its position in Twist Bioscience according to recent filings, while also increasing its stake in X-Energy Inc., which drew attention to position changes across several high growth stocks. Source: X-Energy ARK stake report.
Multiple firms, including Piper Sandler, Canaccord Genuity, and TD Cowen, issued positive research on Twist Bioscience, highlighting its silicon based lab on a chip DNA synthesis technology and use of AI in drug discovery and nucleic acid therapeutics. Source: Analyst ratings summary.
Piper Sandler set an Overweight rating with a US$85 price target and Canaccord Genuity issued a Buy rating with a US$90 price target for Twist Bioscience stock, while some commentary also flagged valuation and profitability risks. Source: Analyst ratings summary.
Company filings showed insider selling of Twist Bioscience stock totaling about US$10.6 million over the past three months, which some investors may view as a signal to review management’s alignment and timing. Source: Insider activity summary.
Twist Bioscience announced a collaboration with LenioBio to pair Twist DNA manufacturing and automation with LenioBio’s ALiCE cell free protein expression platform, aiming to speed up design, build, test cycles for AI driven protein and antibody discovery. Source: Company client announcement.
The company expanded its clonal genes portfolio with an early access launch of Complex Genes, designed to accept approximately 99.5% of clonal gene orders and 99.9% of all DNA products, including sequences that have historically been difficult to manufacture at scale, such as long repeats and high or low GC content regions. Source: Product related announcement.
Twist Bioscience recently hosted an Analyst and Investor Day, providing the market with an updated view on its operations, product roadmap, and financial priorities. Source: Analyst and Investor Day event listing.

Valuation Changes for Twist Bioscience

Fair Value: The analyst fair value estimate for Twist Bioscience stock has increased from $64.38 to $71.10, reflecting a higher assessed worth per share in the current model.
Discount Rate: The discount rate used in the valuation has moved slightly from 7.15% to about 7.14%, indicating only a minimal adjustment to the required return assumption.
Revenue Growth: The long term revenue growth assumption has increased from about 16.13% to roughly 17.27%, indicating a modestly higher expected top line expansion in the updated framework.
Net Profit Margin: The assumed net profit margin has edged slightly lower from approximately 19.04% to about 18.98%, indicating a small reduction in expected long term profitability.
Future P/E: The future P/E multiple applied in the model has increased from about 44.1x to roughly 47.4x, indicating a somewhat richer valuation multiple in the refreshed assumptions.

0 views

Key Takeaways

Broadening customer base, innovative product launches, and industry tailwinds are driving sustained growth and widening Twist's market opportunity.
Increased operational efficiency, product diversification, and global market trends support expanding margins and improved long-term earnings stability.
Heavy customer concentration, ongoing losses, volatile margins, and stagnant emerging market growth threaten revenue stability, profitability, and long-term competitive positioning in dynamic genomics markets.

Catalysts

About Twist Bioscience

Manufactures and sells synthetic DNA-based products.What are the underlying business or industry changes driving this perspective?

Expansion of Twist's customer base, especially among smaller academic clients and long-tail customers, combined with the successful rollout of new synthetic biology (SynBio) product lines, is likely to drive sustained top-line growth and broaden the company's addressable market, positively impacting future revenue.
High demand from large pharma, biotechnology, and clinical diagnostic customers for personalized medicine, genomics, and next-generation sequencing (NGS) services continues to accelerate, supported by long-term increases in global life sciences R&D investment, which should fuel ongoing revenue growth and earnings stability.
Continuous product innovation, including new gene fragment offerings and anticipated upcoming product launches, reflects strategic reinvestment into R&D and manufacturing infrastructure, supporting scalability and improved gross margins over the medium to long term.
Significant improvements in gross margin (now above 50%) through volume leverage, process improvements, and increased vertical integration signal ongoing margin expansion and a clear near-term path toward adjusted EBITDA breakeven, indicating robust future earnings potential.
Diversification across multiple end markets and geographies, coupled with strong underlying industry trends like AI-driven drug discovery and global genomics market expansion, provides resilience against market cycles and supports steady, long-term revenue and profit growth.

Twist Bioscience Earnings and Revenue Growth

Twist Bioscience Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Twist Bioscience's revenue will grow by 17.3% annually over the next 3 years.
Analysts are not forecasting that Twist Bioscience will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Twist Bioscience's profit margin will increase from -19.8% to the average US Biotechs industry of 19.0% in 3 years.
If Twist Bioscience's profit margin were to converge on the industry average, you could expect earnings to reach $125.4 million (and earnings per share of $1.83) by about June 2029, up from -$81.3 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 47.7x on those 2029 earnings, up from -63.5x today. This future PE is greater than the current PE for the US Biotechs industry at 16.4x.
Analysts expect the number of shares outstanding to grow by 3.16% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.14%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Twist Bioscience remains unprofitable, with an expected adjusted EBITDA loss of $45 million to $47 million for fiscal 2025, and only a goal-not a guarantee-to achieve breakeven in 2026; persistent negative operating margins increase the risk of future dilution or an eventual capital raise, which could weigh on earnings per share and shareholder value over time.
A substantial portion of NGS (Next-Generation Sequencing) revenue is concentrated with a small number of large customers-44% of NGS revenue comes from just the top 10 customers-meaning revenue could be volatile or contract sharply if any of these relationships weaken or are lost, posing a risk to recurring revenue stability and overall top line growth.
The company's guidance and margin improvements partly benefited from favorable order timing and mix in recent quarters, which may not repeat; this creates uncertainty about true underlying margin expansion and raises concerns over the sustainability of gross margins and predictable revenue growth into future periods.
Intense competition and potential commoditization in both the NGS and SynBio markets are acknowledged, especially as the company broadens market access and pursues smaller accounts or academic/government customers; this could lead to downward pricing pressure, compress gross margins, and limit future profitability as competition intensifies or innovation outpaces the company's offerings.
Growth in the APAC region remains stagnant and total revenue exposure to China is minimal (approximately 1.5% of Q3 revenue), limiting Twist's ability to capitalize on the rapid expansion of genomics markets in major emerging economies, which may restrict long-term revenue diversification and growth opportunities compared to industry peers who succeed in these markets.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $71.1 for Twist Bioscience based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $90.0, and the most bearish reporting a price target of just $36.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $660.4 million, earnings will come to $125.4 million, and it would be trading on a PE ratio of 47.7x, assuming you use a discount rate of 7.1%.
Given the current share price of $82.87, the analyst price target of $71.1 is 16.6% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Twist Bioscience?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

TWST: Share Valuations Will Stabilize As End Markets Remain Strong